Vancouver, British Columbia--(Newsfile Corp. - July 10, 2025) - Moss Genomics Inc. (CSE: MOSS) (FSE: F73) (OTCQB: MSSGF) (the "Company" or "Moss") is providing an update on its Ethereum (ETH) Treasury Strategy. As part of this strategy, the Company has contributed 200 ETH with a commitment to contribute an additional 800 ETH to the presale of STRAT, an on-chain smart contract that enables ETH-based capital flows through algorithmic expansion and redemption mechanisms.This contribution complements Moss's br ...

Industry Overview - The field of genomics has rapidly evolved over the past decade, focusing on the complete set of genes and their interactions rather than individual genes [1] - Genomics is pivotal for developing targeted therapies, leading to a revolutionary era in genetic medicine, attracting significant attention from pharmaceutical and biotech companies [2] Technological Innovations - Synthetic biology, which applies engineering principles to biology, has emerged as a key concept within genomics, aiding in drug discovery, disease detection, and gene editing [3] - The cost, accuracy, and time required to map an individual's genome have drastically reduced, enhancing the spotlight on genomics companies [4] Market Potential - The genomics market is projected to reach $157.47 billion by 2033, while the global synthetic biology market was valued at $16.22 billion in 2024, with a projected CAGR of 17.30% from 2025 to 2030 [6] Company Highlights - MeiraGTx Holdings plc is focused on genetic medicine with a pipeline addressing conditions like Parkinson's disease and retinal dystrophy, showing promising efficacy data [8][9] - Beam Therapeutics is advancing base editing programs for genetic diseases, with FDA orphan drug designation for its BEAM-101 treatment for sickle cell disease [12][13] - Krystal Biotech received FDA approval for Vyjuvek, the first gene therapy for dystrophic epidermolysis bullosa, and is advancing a pipeline in various therapeutic areas [14][15]

UNIONDALE, NY, June 26, 2025 (GLOBE NEWSWIRE) -- ProPhase Labs Inc. (NASDAQ: PRPH), (the “Company” or “ProPhase”) a next generation biotech, genomics and consumer products company, today announced that it has received an extension of 180 calendar days (the "Extension Notice") from The Nasdaq Stock Market LLC ("Nasdaq") to regain compliance with the Nasdaq's minimum $1.00 bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on Nasdaq (the "Bid Price Requirement"), following ...

Welcome to the Bloomberg Tech Conference. This is our annual event where we bring together a powerhouse lineup of big tech voices. Oh, we're going to be doing a live taping of the circuit today.So, Dylan, our director of photography, is here up from LA. Look at his little shirt. Says the circuit on it.Say hi for the socials. Hi for the socials. 1 2 3 4 5 6 7 8 9 10.So excited. Please welcome to the stage Jennifer Dana, Nobel Laurate in chemistry and founder of the innovative genomics institute for a convers ...

Core Insights - Tempus AI, Inc. (NASDAQ: TEM) is a technology company focused on precision medicine, primarily in genomics and data services, with a recent expansion into AI applications for healthcare [1] Company Overview - The company's core business revolves around genomics and data services, which has shown impressive growth [1] - Tempus AI is now integrating artificial intelligence into its healthcare solutions, indicating a strategic shift towards advanced technology applications [1] Growth and Expansion - The expansion into AI for healthcare applications has contributed to the company's growth trajectory, highlighting its commitment to innovation in the medical field [1]

Core Insights - Roche has announced a strategic collaboration with Broad Clinical Labs to develop applications using its next-generation sequencing (NGS) Sequencing By Expansion (SBX) technology, aiming to transform clinical genomics and biomedical discovery [1][5] - The initial project will focus on trio-based whole genome sequencing for critically ill newborns and their biological parents, with the goal of integrating whole genome sequencing into routine clinical care in neonatal intensive care units (NICUs) [2][8] - The SBX technology is designed for fast, scalable sequencing solutions, offering ultra-fast turnaround times, exceptional scalability, and cost efficiency, making it suitable for various genomic applications [3][9] Company Overview - Roche is a leading biotechnology company and global leader in in-vitro diagnostics, founded in 1896, with a commitment to advancing precision medicine and improving healthcare outcomes [12] - Broad Clinical Labs, a subsidiary of the Broad Institute of MIT and Harvard, specializes in human whole genome sequencing and has sequenced over 750,000 genomes, focusing on understanding and diagnosing human diseases [11] Technology Highlights - The SBX technology offers high-throughput performance with a flexible workflow, enabling rapid deployment in time-sensitive settings like NICUs and supporting comprehensive multi-omic discovery research [3][4] - It includes advanced, high-throughput CMOS sensor modules that allow for ultra-rapid, real-time base calls and analysis, enhancing scalability and flexibility for various project sizes [7][9] - The collaboration will also explore RNA sequencing capabilities, leveraging longer reads of the SBX technology to gain novel molecular insights and identify new therapeutic targets [4][9]

Industry Overview - The rapid evolution of genomics is leading to a revolutionary era in genetic medicine, driven by the need for innovative medical treatments [1] - Genomics focuses on the complete set of genes and their interactions, rather than individual genes, which is attracting attention from pharma and biotech companies [2] - Breakthroughs in genomics have enabled the development of targeted therapies based on individual genetic information [2] - The genomics market is projected to reach $157.47 billion by 2033, while the global synthetic biology market was valued at $16.22 billion in 2024 and is expected to grow at a CAGR of 17.30% from 2025 to 2030 [6] Key Companies - Illumina (ILMN) is a major player in the genomics sector, known for its sequencing and array-based solutions for genetic analysis [4] - Gene editing companies like BEAM Therapeutics (BEAM) and CRISPR Therapeutics AG (CRSP) are developing technologies such as CRISPR/Cas9 to treat diseases caused by genetic variants [5] Investment Opportunities - Intellia Therapeutics (NTLA) is focused on CRISPR-based therapies for diseases with high unmet needs, with lead candidates in phase III studies [8][9] - uniQure (QURE) is advancing gene therapies for conditions like Huntington's disease and has received Breakthrough Therapy designation for AMT-130 [11][12] - Verve Therapeutics (VERV) is developing gene editing medicines for cardiovascular disease, targeting genes like PCSK9 and ANGPTL3 [14][15]

Core Insights - ProPhase Labs is undergoing significant operational transformations aimed at reducing overhead and aligning resources with high-value opportunities, particularly in the biotech and genomics sectors [5][17] - The company anticipates multiple liquidity events in the coming months, including the potential sale of its subsidiary Nebula Genomics and recovery of insurance payments through Crown Medical Collections [7][10][11] Financial Performance - For Q1 2025, ProPhase reported net revenue of $1.4 million, a decrease from $2.4 million in Q1 2024, primarily due to a $1.0 million drop in consumer products revenue [20] - The cost of revenues for Q1 2025 was $0.9 million, leading to a gross margin profit of $0.5 million, compared to a gross margin loss of $0.1 million in Q1 2024 [21][22] - General and administrative expenses decreased to $4.1 million in Q1 2025 from $7.3 million in Q1 2024, reflecting cost-cutting measures [23] - The net loss from continuing operations for Q1 2025 was $4.7 million, or $(0.13) per share, an improvement from a loss of $5.5 million, or $(0.32) per share, in Q1 2024 [25] Strategic Developments - The company completed the divestiture of its Pharmaloz manufacturing operations for approximately $23 million, saving over $2 million annually [4] - ProPhase is pursuing strategic alternatives for Nebula Genomics, which has a unique 16-petabyte DNA dataset, and expects to receive letters of intent from potential acquirers soon [7][8] - The BE-Smart Esophageal Cancer Test has been submitted for peer review, with commercialization expected later this year, following a favorable ruling on laboratory-developed tests [12][14][16] Cash Flow and Liquidity - As of March 31, 2025, ProPhase had cash and cash equivalents of $88,000, down from $678,000 at the end of 2024, primarily due to cash used in operating activities [26] - The company is optimistic about generating significant cash flow from Crown Medical Collections, which estimates a recovery of approximately $50 million in insurance payments [10][11] Market Position and Future Outlook - ProPhase Labs aims to position itself as a leader in precision diagnostics, particularly in gastroenterology, with its proprietary BE-Smart platform [16] - The company is focused on unlocking value through strategic asset development and disciplined execution, with several major milestones anticipated in the near future [17]

Group 1: Carl Icahn's Investment Moves - Carl Icahn significantly increased his stake in Illumina Inc. by 450%, adding 180,000 shares to reach a total of 220,000 shares, which now represents 0.25% of his $7 billion portfolio, up from 0.07% [1][2] - Icahn's investment in JetBlue Airways Corp. saw an 89.66% increase, with nearly 15.9 million shares purchased, bringing his total to 33.6 million shares valued at over $162 million, making it the 7th largest position in his portfolio [3][4] - The latest moves indicate Icahn's confidence in both Illumina and JetBlue, suggesting potential turnaround opportunities in the biotech and airline sectors [3][4] Group 2: Portfolio Composition - Illumina ranks 13th in Icahn's portfolio and is one of his top percentage gainers this quarter, reflecting renewed conviction in the company amid challenges [2] - Icahn's top three healthcare holdings now include Bausch Health Companies Inc., Bausch + Lomb Corp., and Illumina, showcasing a diverse mix across pharma, optics, and biotech [2] - Despite increasing stakes in Illumina and JetBlue, Icahn reduced his exposure to Southwest Gas Holdings Inc., which saw a 1.96% drop in portfolio allocation [4]

Summary of 10X Genomics (TXG) 2025 Conference Call Company Overview - **Company**: 10X Genomics (TXG) - **Date of Conference**: May 13, 2025 Key Points Industry Context - The macroeconomic environment has changed significantly, impacting funding for customers, particularly in U.S. academic and government markets [4][10][12] - There is ongoing uncertainty regarding future funding and budget allocations, leading to cautious spending among customers [10][11][12] Financial Performance - The company reported robust growth in reactions and volumes for Chromium consumables, indicating strong fundamentals despite macro pressures [6][7] - The first quarter guidance was suspended due to uncertainty, but a quarterly guidance was provided with a projected growth of 1% from Q1 to Q2 [13][15] - The company experienced a 22% growth in China, indicating strong international performance [17] Product Development and Market Position - The introduction of new products aimed at lowering the price per reaction has driven growth in the single-cell market [6][38] - The Xenium platform is gaining traction, with customers increasingly recognizing its value alongside single-cell technologies [30][32] - The company is focused on expanding its product offerings and improving customer experience to maintain a competitive edge [44][46] Customer Insights and Trends - Customers are showing a preference for established brands during uncertain budget periods, which benefits 10X Genomics [48] - There is a growing demand for both single-cell and spatial technologies, with customers increasingly seeing them as complementary rather than competitive [30][31] Competitive Landscape - The competitive environment remains challenging, but 10X Genomics believes its product quality and customer service will help retain market share [44][46] - The company is actively addressing pricing concerns to remain competitive while ensuring product value [47][48] Future Outlook - The company is optimistic about the long-term growth potential in the biopharma sector, with plans to enhance commercial infrastructure and focus on routine use of its technologies [58][59][60] - Sustained progress is expected to take time, but there is confidence in achieving growth comparable to academic markets [60] Additional Insights - The company has made significant changes to its sales force, focusing on dedicated teams for biopharma accounts and Xenium instruments [49][50] - Cost-cutting measures were implemented, particularly in R&D, to maintain financial health without undermining sales efforts [52] This summary encapsulates the key insights and developments discussed during the conference call, highlighting the company's performance, market dynamics, and strategic direction.